Who Paid My Doc Search
Menu
Organisation paid for research Program year 2024 Source: CMS Open Payments

Elite Clinical Studies, LLC

Neither a doctor nor a teaching hospital

Research payments

$568,657

74 payments

Through program year 2024, Elite Clinical Studies, LLC is reported as receiving $568,657 in research payments, across 74 payments.

By program year

5 rows
Year Kind Amount Payments
2024 Research $25,867 2
2023 Research $95,728 8
2022 Research $67,575 12
2020 Research $31,391 12
2019 Research $348,097 40

Breakdown

Who paid Research payments · program years 2019–2024
  1. Hikma Pharmaceuticals USA $185,842 8 payments
  2. Mylan Specialty L.P. $166,669 18 payments
  3. AstraZeneca AB $65,407 4 payments
  4. AbbVie, Inc. $64,160 15 payments
  5. AstraZeneca Pharmaceuticals LP $42,208 7 payments
  6. Gilead Sciences, Inc. $20,734 12 payments
  7. Teva Pharmaceuticals USA, Inc. $17,420 7 payments
  8. Kowa Research Institute, Inc. $5,123 2 payments
  9. E.R. Squibb & Sons, L.L.C. $1,095 1 payment
Studies the money was for Research payments · program years 2019–2024
  1. Fluticasone Salmeterol Powder, 100mcg50mcg Multicenter Clinical Endpoint Study $185,188 7 payments
  2. A Phase 4, Randomized, Double-Blind, Double-Dummy, Parallel Group Study Comparing Improvements in Lung Function in Adults With Severe to Very Severe Chronic Obstructive Pulmonary Disease and Suboptimal Inspiratory Flow Rate Following Once-Daily Treatment Over 12 Weeks With Either Revefenacin Inhalation Solution Delivered via Standard Jet Nebulizer or Tiotropium Delivered via a Dry Powder Inhaler (Spiriva HandiHaler) $95,728 8 payments
  3. A Phase 2b Randomised, Double Blind, Placebo Controlled, Parallel Arm, Multi Centre Study to Assess Efficacy and Safety of Multiple Dose Levels of AZD7594 DPI Given Once Daily for twelve weeks, compared to placebo, in Asthmatics symptomatic on low dose ICS $65,407 4 payments
  4. M16-100 $58,161 11 payments
  5. A Phase 4, Randomized, Double-Blind, Double-Dummy, Parallel Group Study Comparing Improvements in Lung Function in Adults With Severe to Very Severe Chronic Obstructive Pulmonary Disease and Suboptimal Inspiratory Flow Rate Following Once-Daily Treatment Over 12 Weeks With Either Revefenacin Inhalation Solution Delivered via Standard Jet Nebulizer or Tiotropium Delivered via a Dry Powder Inhaler (Spiriva HandiHaler) $45,074 8 payments
  6. A Phase 4, Randomized, Double-Blind, Double-Dummy, Parallel?Group Study Comparing Improvements in Lung Function in Adults With Severe to Very Severe Chronic Obstructive Pulmonary Disease and Suboptimal Inspiratory Flow Rate Following Once-Daily Treatment Over 12 Weeks With Either Revefenacin Inhalation Solution Delivered via Standard Jet Nebulizer or Tiotropium Delivered via a Dry Powder Inhaler (Spiriva HandiHaler) $25,867 2 payments
  7. A Randomized Double-Blind Parallel Group Multi-Center 24-Week Study Comparing the Efficacy and Safety of Three Doses of PT001 to Placebo and Open-label Spiriva Respimat in Subjects With Persistent Asthma $20,803 4 payments
  8. A Randomized, Blinded, Parallel Group, Placebo-Controlled, Multiple Dose, Multicenter Study to Compare the Therapeutic Equivalence of Fluticasone Propionate Pressurized Metered Dose Inhaler, 110 mcg, to Flovent HFA 110 mcg, in Adult Subjects With Asthma $17,420 7 payments
  9. A Randomized Double Blind Double Dummy Parallel Group Multicenter 24 to 52 Week Variable Length Study to Assess the Efficacy and Safety of Budesonide Glycopyrronium and Formoterol Fumarate Metered Dose Inhaler $13,406 2 payments
  10. Onset of Effect Questionnaire $8,000 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2024

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record